| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| AUPHAurinia Pharmaceuticals Inc. | 1.96B | 14.87 | 378.37 | 33.97% | 29.28% | 21.28% | 2.25% | 0.21 |
| ARGXargenx SE | 50.33B | 813.24 | 63.63 | 78.6% | 23.34% | 15.14% | 0.01 | |
| INVAInnoviva, Inc. | 1.48B | 19.76 | 54.89 | 15.54% | 32.78% | 12.61% | 12.75% | 0.65 |
| GLPGGalapagos N.V. | 2.24B | 34.03 | 30.38 | 14.99% | -151.94% | -15.16% | 0.00 | |
| PTGXProtagonist Therapeutics, Inc. | 5.3B | 84.75 | 20.04 | 6.24% | 21.94% | 7.11% | 3.45% | 0.02 |
| ALMSAlumis Inc. Common Stock | 2.84B | 24.17 | -2.33 | -11.08% | -63.71% | 0.12 | ||
| PHATPhathom Pharmaceuticals, Inc. | 1.17B | 14.98 | -2.83 | 80.01% | -186.53% | |||
| ORKAOruka Therapeutics, Inc. | 1.57B | 32.50 | -6.51 | -22.44% | 0.00 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 164.72K | 169.5K | 844.75K | 3.82M | 2.03M | 763K | 853K | 810K | 743K | 674K |
| Revenue Growth % | - | 0.03% | 3.98% | 3.52% | -0.47% | -0.62% | 0.12% | -0.05% | -0.08% | -0.09% |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 164.72K | 169.5K | 844.75K | 3.82M | 2.03M | 763K | 853K | 810K | 743K | 674K |
| Gross Margin % | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1% |
| Gross Profit Growth % | - | 0.03% | 3.98% | 3.52% | -0.47% | -0.62% | 0.12% | -0.05% | -0.08% | -0.09% |
| Operating Expenses | 6.58M | 8.8M | 8.22M | 9.23M | 14.04M | 14.9M | 13.7M | 10.91M | 8.94M | 8.8M |
| OpEx % of Revenue | 39.95% | 51.94% | 9.73% | 2.42% | 6.91% | 19.53% | 16.06% | 13.46% | 12.03% | 13.06% |
| Selling, General & Admin | 2.7M | 2.7M | 2.95M | 3.16M | 3.06M | 2.95M | 3.85M | 3.14M | 2.96M | 3.05M |
| SG&A % of Revenue | 16.39% | 15.91% | 3.49% | 0.83% | 1.51% | 3.87% | 4.51% | 3.88% | 3.98% | 4.52% |
| Research & Development | 3.86M | 6.08M | 5.27M | 6.08M | 10.98M | 11.95M | 9.85M | 7.76M | 5.98M | 5.76M |
| R&D % of Revenue | 23.41% | 35.86% | 6.24% | 1.59% | 5.4% | 15.66% | 11.55% | 9.58% | 8.05% | 8.54% |
| Other Operating Expenses | 24.08K | 28.86K | 31.07K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -6.42M | -8.63M | -7.38M | -5.41M | -12.01M | -14.14M | -12.84M | -10.1M | -8.2M | -8.13M |
| Operating Margin % | -38.95% | -50.94% | -8.73% | -1.42% | -5.91% | -18.53% | -15.06% | -12.46% | -11.03% | -12.06% |
| Operating Income Growth % | 0.1% | -0.35% | 0.15% | 0.27% | -1.22% | -0.18% | 0.09% | 0.21% | 0.19% | 0.01% |
| EBITDA | -6.4M | -8.62M | -7.36M | -5.4M | -11.99M | -14.13M | -12.83M | -10.08M | -8.18M | -8.12M |
| EBITDA Margin % | -38.85% | -50.83% | -8.71% | -1.41% | -5.9% | -18.52% | -15.04% | -12.45% | -11.01% | -12.05% |
| EBITDA Growth % | 0.1% | -0.35% | 0.15% | 0.27% | -1.22% | -0.18% | 0.09% | 0.21% | 0.19% | 0.01% |
| D&A (Non-Cash Add-back) | 16.39K | 18.46K | 19.85K | 14K | 14K | 12K | 14K | 14K | 15K | 7K |
| EBIT | -6.42M | -8.36M | -6.4M | -6.14M | -12.01M | -14.14M | -12.84M | -10.1M | -8.2M | -8.13M |
| Net Interest Income | 1.35M | 61.74K | 41K | 33K | -376K | -343K | 6K | 206K | 492K | 277K |
| Interest Income | 1.92M | 89.09K | 69K | 51K | 72K | 44K | 24K | 222K | 506K | 291K |
| Interest Expense | 564.34K | 27.35K | 28K | 18K | 448K | 387K | 18K | 16K | 14K | 14K |
| Other Income/Expense | 1.35M | 269.86K | 781K | -1.15M | -618K | -304K | 227K | -77K | 561K | 250K |
| Pretax Income | -5.06M | -6.99M | -4.95M | -6.57M | -12.63M | -14.44M | -12.62M | -10.17M | -7.63M | -7.88M |
| Pretax Margin % | -30.72% | -41.25% | -5.86% | -1.72% | -6.21% | -18.93% | -14.79% | -12.56% | -10.27% | -11.69% |
| Income Tax | 4.36K | 29.12K | 29.92K | 4K | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0.95% | 0.99% | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1% |
| Net Income | -4.8M | -6.9M | -4.97M | -6.57M | -12.63M | -14.44M | -12.6M | -10.17M | -7.63M | -7.88M |
| Net Margin % | -29.12% | -40.69% | -5.88% | -1.72% | -6.21% | -18.93% | -14.77% | -12.56% | -10.27% | -11.69% |
| Net Income Growth % | 0.21% | -0.44% | 0.28% | -0.32% | -0.92% | -0.14% | 0.13% | 0.19% | 0.25% | -0.03% |
| Net Income (Continuing) | -5.06M | -8.39M | -6.43M | -6.57M | -12.63M | -14.44M | -12.62M | -10.17M | -7.63M | -7.88M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 129.11K | 8.58K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -81.00 | -90.00 | -57.00 | -51.00 | -45.00 | -12.69 | -8.25 | -3.75 | -1.80 | -1.08 |
| EPS Growth % | 0.23% | -0.11% | 0.37% | 0.11% | 0.12% | 0.72% | 0.35% | 0.55% | 0.52% | 0.4% |
| EPS (Basic) | -81.00 | -90.00 | -57.00 | -51.00 | -45.00 | -12.69 | -9.00 | -3.75 | -1.80 | -1.08 |
| Diluted Shares Outstanding | 76.51K | 92.31K | 108.42K | 129.67K | 286.37K | 1.19M | 1.84M | 2.72M | 4.26M | 7.25M |
| Basic Shares Outstanding | 76.51K | 92.31K | 108.42K | 129.67K | 286.37K | 1.14M | 1.53M | 2.72M | 4.26M | 7.25M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 17.53M | 10.1M | 6.87M | 7.9M | 7.14M | 9.4M | 20.07M | 9.16M | 9.91M | 8.98M |
| Cash & Short-Term Investments | 16.91M | 8.11M | 3.5M | 3.89M | 2.76M | 8.34M | 19.14M | 7.98M | 8.92M | 7.89M |
| Cash Only | 16.91M | 8.11M | 3.5M | 3.62M | 2.7M | 8.27M | 4.39M | 2.98M | 4.28M | 4.83M |
| Short-Term Investments | 0 | 0 | 0 | 273K | 64K | 75K | 14.75M | 5M | 4.64M | 3.06M |
| Accounts Receivable | 61.99K | 21.84K | 0 | 0 | 637K | 18K | 48K | 47K | 78K | 77K |
| Days Sales Outstanding | 137.37 | 47.02 | - | - | 114.42 | 8.61 | 20.54 | 21.18 | 38.32 | 41.7 |
| Inventory | -620.81K | 0 | -3.3M | 0 | -715K | 0 | -48K | -39K | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 558.82K | 0 | 0 | 41K | 729K | 0 | 48K | 47K | 0 | 1.02M |
| Total Non-Current Assets | 67.37K | 62.91K | 965.88K | 49K | 1.03M | 123K | 185K | 126K | 81K | 138K |
| Property, Plant & Equipment | 60.46K | 53.29K | 46.03K | 47K | 118K | 123K | 185K | 126K | 81K | 138K |
| Fixed Asset Turnover | 2.72x | 3.18x | 18.35x | 81.28x | 17.22x | 6.20x | 4.61x | 6.43x | 9.17x | 4.88x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 914.66K | 0 | 0 | 0 | 0 | 8K | 0 | 0 |
| Other Non-Current Assets | 6.92K | 9.62K | 5.18K | 2K | 912K | 0 | 0 | -8K | 0 | 0 |
| Total Assets | 17.6M | 10.17M | 7.83M | 7.95M | 8.17M | 9.52M | 20.25M | 9.28M | 9.99M | 9.12M |
| Asset Turnover | 0.01x | 0.02x | 0.11x | 0.48x | 0.25x | 0.08x | 0.04x | 0.09x | 0.07x | 0.07x |
| Asset Growth % | 0.73% | -0.42% | -0.23% | 0.02% | 0.03% | 0.17% | 1.13% | -0.54% | 0.08% | -0.09% |
| Total Current Liabilities | 1.78M | 2.5M | 1.8M | 3.12M | 3.27M | 1.27M | 2.73M | 2.5M | 2.02M | 2.05M |
| Accounts Payable | 461.87K | 1.25M | 427K | 1.07M | 2.16M | 561K | 954K | 896K | 427K | 618K |
| Days Payables Outstanding | - | - | - | - | - | - | - | - | - | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 43K | 53K | 48K | 27K | 53K |
| Deferred Revenue (Current) | 219.54K | 321.58K | 373.75K | 926K | 469K | 334K | 818K | 783K | 622K | 405K |
| Other Current Liabilities | 149.35K | 669K | 268.39K | 149K | 165K | 53K | 550K | 444K | 667K | 622K |
| Current Ratio | 9.86x | 4.04x | 3.82x | 2.53x | 2.18x | 7.41x | 7.35x | 3.66x | 4.90x | 4.38x |
| Quick Ratio | 10.21x | 4.04x | 5.66x | 2.53x | 2.40x | 7.41x | 7.37x | 3.68x | 4.90x | 4.38x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 5.38M | 3.79M | 2.98M | 1.82M | 2.46M | 2.18M | 3.14M | 2.31M | 1.73M | 1.63M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 39K | 24K | 71K | 14K | 13K | 51K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | -2.42M | -2.16M | -3.07M | -2.29M | 0 | 0 |
| Other Non-Current Liabilities | 4.45M | 2.62M | 2.14M | 0 | 1.57M | 2.16M | 3.07M | 2.29M | 0 | 0 |
| Total Liabilities | 7.16M | 6.29M | 4.78M | 4.94M | 5.73M | 3.45M | 5.87M | 4.81M | 3.75M | 3.68M |
| Total Debt | 0 | 0 | 0 | 0 | 75K | 67K | 124K | 62K | 40K | 104K |
| Net Debt | -16.91M | -8.11M | -3.5M | -3.62M | -2.62M | -8.2M | -4.27M | -2.92M | -4.24M | -4.72M |
| Debt / Equity | - | - | - | - | 0.03x | 0.01x | 0.01x | 0.01x | 0.01x | 0.02x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -11.37x | -315.66x | -263.42x | -300.78x | -26.80x | -36.53x | -713.44x | -631.04x | -585.36x | -580.71x |
| Total Equity | 10.44M | 3.87M | 3.05M | 3.02M | 2.44M | 6.07M | 14.38M | 4.47M | 6.24M | 5.44M |
| Equity Growth % | 0.52% | -0.63% | -0.21% | -0.01% | -0.19% | 1.49% | 1.37% | -0.69% | 0.4% | -0.13% |
| Book Value per Share | 136.52 | 41.97 | 28.17 | 23.25 | 8.53 | 5.08 | 7.80 | 1.64 | 1.47 | 0.75 |
| Total Shareholders' Equity | 10.32M | 3.87M | 3.05M | 3.02M | 2.44M | 6.07M | 14.38M | 4.47M | 6.24M | 5.44M |
| Common Stock | 1.8M | 1.83M | 2.39M | 2.63M | 8.22M | 33.04M | 60.65M | 0 | 0 | 0 |
| Retained Earnings | -82.71M | -90.98M | -105.66M | -100.62M | -110.31M | -125.47M | -140.67M | -150.85M | -158.48M | -166.36M |
| Treasury Stock | -929.38K | -943.17K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 4.58M | 5.08M | 6.28M | 6.93M | 1.13M | 1.13M | 1.13M | 1.13M | 1.13M | 1.13M |
| Minority Interest | 129.11K | 8.58K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -4.65M | -8.93M | -9.52M | -4.16M | -10.83M | -12.06M | -9.86M | -10.8M | -8.44M | -7.64M |
| Operating CF Margin % | -28.24% | -52.67% | -11.27% | -1.09% | -5.33% | -15.81% | -11.56% | -13.33% | -11.36% | -11.33% |
| Operating CF Growth % | 0.37% | -0.92% | -0.07% | 0.56% | -1.61% | -0.11% | 0.18% | -0.1% | 0.22% | 0.1% |
| Net Income | -5.06M | -7.02M | -4.98M | -6.57M | -12.63M | -14.44M | -12.62M | -10.17M | -7.63M | -7.88M |
| Depreciation & Amortization | 16.39K | 18.46K | 19.85K | 14K | 14K | 12K | 14K | 14K | 15K | 7K |
| Stock-Based Compensation | 109K | 309K | 195.07K | 535K | 385K | 355K | 466K | 263K | 261K | 362K |
| Deferred Taxes | 0 | 0 | 278.51K | 0 | 212K | 11K | -94K | 0 | 0 | 0 |
| Other Non-Cash Items | -1.09M | -1.47M | -2.59M | 733K | -5K | 1K | -59K | 396K | -139K | 141K |
| Working Capital Changes | 1.49M | -449.49K | -2.45M | 1.13M | 1.19M | 2M | 2.43M | -1.3M | -943K | -267K |
| Change in Receivables | 255.15K | -1.37M | -1.16M | -853K | 270K | 2.73M | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 125K | -316K | 1.27M | 0 | 0 | 0 | 0 |
| Change in Payables | 78.9K | 591.95K | -964.15K | 644K | 1.08M | -1.59M | 393K | -58K | -469K | 191K |
| Cash from Investing | -42.78K | -10.4K | -29.64K | -33K | -253K | -26K | -14.51M | 9.5M | 498K | 1.5M |
| Capital Expenditures | -45.34K | -10.4K | -6.91K | -33K | -3K | -26K | -11K | -9K | -2K | -5K |
| CapEx % of Revenue | 0.28% | 0.06% | 0.01% | 0.01% | 0% | 0.03% | 0.01% | 0.01% | 0% | 0.01% |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 2.56K | 0 | -22K | 0 | -250K | 0 | 0 | 9.51M | 500K | 1.5M |
| Cash from Financing | 12.38M | 0 | 4.88M | 4.39M | 10.17M | 17.68M | 20.46M | 0 | 9.14M | 6.71M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | 0 | 0 | 0 | 0 | 34K | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -4.7M | -8.94M | -9.53M | -4.19M | -10.84M | -12.09M | -9.87M | -10.81M | -8.44M | -7.64M |
| FCF Margin % | -28.52% | -52.73% | -11.28% | -1.1% | -5.33% | -15.84% | -11.57% | -13.35% | -11.36% | -11.34% |
| FCF Growth % | 0.36% | -0.9% | -0.07% | 0.56% | -1.59% | -0.12% | 0.18% | -0.1% | 0.22% | 0.09% |
| FCF per Share | -61.39 | -96.83 | -87.90 | -32.30 | -37.84 | -10.12 | -5.35 | -3.98 | -1.98 | -1.05 |
| FCF Conversion (FCF/Net Income) | 0.97x | 1.29x | 1.92x | 0.63x | 0.86x | 0.84x | 0.78x | 1.06x | 1.11x | 0.97x |
| Interest Paid | 0 | 0 | 23K | 18K | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 4.1K | 29K | 29K | 4K | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -55.45% | -96.34% | -143.44% | -216.55% | -462.71% | -339.2% | -123.14% | -107.91% | -142.49% | -134.94% |
| Return on Invested Capital (ROIC) | - | - | - | - | - | - | -241.12% | -129.75% | -345.2% | -448.35% |
| Gross Margin | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% |
| Net Margin | -2912.29% | -4069.33% | -588.18% | -172.02% | -621.31% | -1892.92% | -1476.55% | -1255.93% | -1027.46% | -1169.14% |
| Debt / Equity | - | - | - | - | 0.03x | 0.01x | 0.01x | 0.01x | 0.01x | 0.02x |
| Interest Coverage | -11.37x | -315.66x | -263.42x | -300.78x | -26.80x | -36.53x | -713.44x | -631.04x | -585.36x | -580.71x |
| FCF Conversion | 0.97x | 1.29x | 1.92x | 0.63x | 0.86x | 0.84x | 0.78x | 1.06x | 1.11x | 0.97x |
| Revenue Growth | - | 2.9% | 398.38% | 352.21% | -46.81% | -62.45% | 11.8% | -5.04% | -8.27% | -9.29% |
Can-Fite BioPharma Ltd. (CANF) reported $0.6M in revenue for fiscal year 2024. This represents a 19% increase from $0.5M in 2011.
Can-Fite BioPharma Ltd. (CANF) saw revenue decline by 9.3% over the past year.
Can-Fite BioPharma Ltd. (CANF) reported a net loss of $8.8M for fiscal year 2024.
Can-Fite BioPharma Ltd. (CANF) has a return on equity (ROE) of -134.9%. Negative ROE indicates the company is unprofitable.
Can-Fite BioPharma Ltd. (CANF) had negative free cash flow of $8.4M in fiscal year 2024, likely due to heavy capital investments.